Primary and Secondary Central Nervous System Involvement in Acute Myeloid Leukemia
Joanna Góra‐Tybor, Agnieszka Pluta, Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Renata Guzicka‐Kazimierczak, Olga Grzybowska‐Izydorczyk, Izabela Dereń-Wagemann, Jarosław Piszcz(Medical University of Białystok), Andrzej Szczepaniak(Poznan University of Medical Sciences), Wanda Knopińska‐Posłuszny, Maciej Kaźmierczak(Silesian University of Technology), W Wiktor-Jędrzejczak, Monika Paluszewska, Marta Barańska(Poznan University of Medical Sciences)
Cited by 9
Related Papers
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
|Blood Advances|2020|109
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2023|106